Adjuvant endocrine therapy in pre- and perimenopausal women with breast cancer: practice guidelines
暂无分享,去创建一个
P. Neven | H. Wildiers | M. Berlière | A. Awada | H. Denys | F. Duhoux
[1] S. Loibl,et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] F. Montemurro,et al. Adjuvant ovarian suppression in premenopausal breast cancer. , 2015, The New England journal of medicine.
[3] F. Cardoso,et al. Breast Cancer Under Age 40: a Different Approach , 2015, Current Treatment Options in Oncology.
[4] J. Forbes,et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. , 2015, The New England journal of medicine.
[5] R. Greil,et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] S. Martino,et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] A. Giobbie-Hurder,et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. , 2014, The New England journal of medicine.
[8] C. Perou,et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] H. Earl,et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Ming-Feng Hou,et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial , 2013, The Lancet.
[11] O. Pagani,et al. Pregnancy after Breast Cancer: Myths and Facts , 2012, Breast Care.
[12] Dawn L Hershman,et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Robert B Livingston,et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. , 2005, Journal of the National Cancer Institute.
[14] M. Piccart,et al. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.